Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Cited by (875)

Items 301–400 of 875

1. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis
   Amro Mohamed Soliman, Srijit Das, Seong Lin Teoh · 2021 · International Journal of Molecular Sciences
2. Mutational landscape reflects the biological continuum of plasma cell dyscrasias
   Andrea Rossi, Minna Voigtlaender, Snjezana Janjetovic, Benjamin Thiele, Malik Alawi, Manuela März, Anna Paula Brandt, Timon Hansen, Janina Radloff, Gerhard Schön et al. · 2017 · Blood Cancer Journal
3. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
   Ana Belén Herrero, Dalia Quwaider, Luis Antonio Corchete, María‐Victoria Mateos, Ramón García‐Sánz, Norma Carmen Gutierrez · 2020 · Journal of Cellular and Molecular Medicine
4. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
   Giada Bianchi, Irene M. Ghobrial · 2014 · Current Cancer Therapy Reviews
5. SCNVSim: somatic copy number variation and structure variation simulator
   Maochun Qin, Biao Liu, Jeffrey M. Conroy, Carl D Morrison, Qiang Hu, Yubo Cheng, Mitsuko Murakami, Adekunle Odunsi, Candace S. Johnson, Lei Wei et al. · 2015 · BMC Bioinformatics
6. Colorectal Cancer Genetic Heterogeneity Delineated by Multi-Region Sequencing
   You-Wang Lu, Huifeng Zhang, Rui Liang, Zhenrong Xie, Hua-You Luo, Yujian Zeng, Yu Xu, Lamei Wang, Xiangyang Kong, Kunhua Wang · 2016 · PLoS ONE
7. Immunologic approaches for the treatment of multiple myeloma
   Leo Rasche, Niels Weinhold, Gareth John Morgan, Frits van Rhee, Faith E. Davies · 2017 · Cancer Treatment Reviews
8. Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study
   Noopur S Raje, Ian Chau, David Michael Hyman, Vincent Ribrag, Jean‐Yves Blay, Josep M. Tabernero, Elena Élez, Jürgen Wolf, Andrew Jenho Yee, Martin Kaiser et al. · 2018 · JCO Precision Oncology
9. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma
   James B. Smadbeck, Jess F. Peterson, Kathryn E. Pearce, Beth A. Pitel, Andrea Lebron Figueroa, Michael Timm, Dragan Jevremović, Min Shi, A. Keith Stewart, Esteban Braggio et al. · 2019 · Blood Cancer Journal
10. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas
    Bin Zhu, Maria Luana Poeta, Manuela Costantini, Tongwu Zhang, Jianxin Shi, Steno Sentinelli, Zhao Wei, Vincenzo Pompeo, Maurizio Cardelli, Boian S. Alexandrov et al. · 2020 · Nature Communications
11. Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases
    Roy Rabbie, Naser Ansari‐Pour, Oliver M. Cast, Doreen Lau, Francis Scott, Sarah Joanne Welsh, Christine Parkinson, Leila Khoja, Luiza Moore, Mark Tullett et al. · 2020 · Nature Communications
12. KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
    Elena Vendramini, Riccardo Bomben, Federico Pozzo, Tamara Bittolo, Erika Tissino, Valter Gattei, Antonella Zucchetto · 2022 · Cancers
13. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing
    Georgina L. Ryland, Kate L. Jones, Melody Chin, John F Markham, Elle Aydogan, Yamuna Kankanige, Marisa Caruso, Jerick Guinto, Michael John Dickinson, Henry Miles Prince et al. · 2018 · Journal of Clinical Pathology
14. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
    Tilmann Bochtler, Maximilian Merz, Thomas Hielscher, Martin Granzow, Korbinian Hoffmann, Alwin Krämer, Marc Steffen Raab, Jens Hillengaß, Anja Seckinger, Christoph Richard Kimmich et al. · 2018 · Blood Advances
15. Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling
    Kevin Dzobo, Arielle Rowe, Dimakatso Alice Senthebane, Mousa AlMazyadi, Victoria A. Patten, Mohamed Iqbal Parker · 2018 · OMICS A Journal of Integrative Biology
16. The utility of non‐invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma
    Xiaolu Long, Qian Xu, Yaoyao Lou, Chunrui Li, Jia Gu, Haodong Cai, Di Wang, Jinhuan Xu, Tongjuan Li, Xiaoxi Zhou et al. · 2020 · British Journal of Haematology
17. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
    Susan Bal, Ehsan Malek, Ankit J. Kansagra, Saad Z. Usmani, Ravi Vij, Kelly Nicole Godby, Robert Frank Cornell, Yubin Kang, Elvira R. Umyarova, Smith Giri et al. · 2021 · Leukemia
18. Single‐cell RNA‐seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma
    Haiyan He, Zifeng Li, Jing Lü, Wanting Qiang, Sihan Jiang, Yaochen Xu, Weijun Fu, Xiaowen Zhai, Lin Zhou, Maoxiang Qian et al. · 2022 · Clinical and Translational Medicine
19. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
    Bustoros, Mark, Anand, Shankara, Sklavenitis-Pistofidis, Romanos, Redd, Robert, Boyle, Eileen M., Zhitomirsky, Benny, Dunford, Andrew J., Tai, Yu-Tzu, Chavda, Selina J., Boehner, Cody et al. · 2022 · Nature Communications
20. The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA
    Simona Segalla, Silvia Pivetti, Katia Todoerti, Malgorzata Agata Chudzik, Erica Claudia Giuliani, Federico Lazzaro, Viviana Volta, Dejan Lazarević, Giovanna Musco, Marco Muzi-Falconi et al. · 2015 · Nucleic Acids Research
21. The landscape of somatic mutation in sporadic Chinese colorectal cancer
    Zhe Liu, Chao Yang, Xiangchun Li, Wen Luo, Bhaskar Roy, Teng Xiong, Xiuqing Zhang, Huanming Yang, jian Zi Wang, Zhenhao Ye et al. · 2018 · Oncotarget
22. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
    Axel Le Cesne, Sebastian Bauer, George D. Demetri, Guangyang Han, Luca Dezzani, Qasim Iftikhar Ahmad, Jean‐Yves Blay, Ian Robert Judson, Patrick Schöffski, Massimo Aglietta et al. · 2019 · BMC Cancer
23. FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity
    Karineh Kazazian, Yosr Z. Haffani, Deanna Wan Jie Ng, Michelle Chae Min Lee, Wendy Johnston, Minji Kim, Roland Xu, Karina Pacholzyk, Francis Si Wai Zih, Julie D. Tan et al. · 2020 · Communications Biology
24. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
    Katia Todoerti, Domenica Ronchetti, Vanessa Katia Favasuli, Francesco Maura, Fortunato Morabito, Niccolò Bolli, Elisa Taìana, Antonino Neri · 2021 · Haematologica
25. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics
    Hassan K. Awada, Bicky Thapa, Hussein Awada, Jing Dong, Carmelo Gurnari, Parameswaran Hari, Binod Dhakal · 2021 · Cells
26. Understanding the origins of human cancer
    Ludmil B. Alexandrov · 2015 · Science
27. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine
    Gerald Goh, Ramona Schmid, Kelly Guiver, Wichit Arpornwirat, Imjai Chitapanarux, Vinod Ganju, Seock‐Ah Im, Sung‐Bae Kim, Arunee Dechaphunkul, Jedzada Maneechavakajorn et al. · 2016 · PLoS Medicine
28. Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma
    Isabel Juliana Hofman, Stephanie Patchett, Mark van Duin, Ellen Geerdens, Jelle Verbeeck, Lucienne Michaux, Michel Delforge, Pieter Sonneveld, Alan M. Johnson, Kim De Keersmaecker · 2017 · Haematologica
29. High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma
    Yu Sun, Amina Aziz, Kristian M. Bowles, Stuart A. Rushworth · 2017 · Cancer Letters
30. Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside
    Aurore Perrot, Jill Corre, Hervé Avet‐Loiseau · 2018 · American Society of Clinical Oncology Educational Book
31. Trio-Based Deep Sequencing Reveals a Low Incidence of Off-Target Mutations in the Offspring of Genetically Edited Goats
    Chao Li, Shiwei Zhou, Yan Li, Guanwei Li, Yige Ding, Lan Li, Jing Liu, Lei Qu, Tad Stewart Sonstegard, Xingxu Huang et al. · 2018 · Frontiers in Genetics
32. Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand
    Shujuan Zhang, Chao Xia, Cong Xu, Jing L. Liu, Han Jian Zhu, Ya Yang, Fei Xu, Juan-Feng Zhao, Ying Chang, Qiu Zhao · 2017 · International Journal of Oncology
33. Genomic landscape of multiple myeloma and its precursor conditions
    Alberge, Jean-Baptiste, Dutta, Ankit K., Poletti, Andrea, Coorens, Tim H. H., Lightbody, Elizabeth D., Toenges, Rosa, Loinaz, Xavi, Wallin, Sofia, Dunford, Andrew, Priebe, Oliver et al. · 2025 · Nature Genetics
34. New horizons in our understanding of precursor multiple myeloma and early interception
    David M. Cordas dos Santos, Rosa Toenges, Luca Bertamini, Jean-Baptiste Alberge, Irene M. Ghobrial · 2024 · Nature reviews. Cancer
35. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma
    Even Holth Rustad, Kristine Misund, Elsa Bernard, Eivind Coward, Venkata D. Yellapantula, Malin L. Hultcrantz, Caleb Ho, Dickran Gano Kazandjian, Neha Korde, Sham Mailankody et al. · 2019 · American Journal of Hematology
36. Liquid biopsies for multiple myeloma in a time of precision medicine
    Bruna Velosa Ferreira, Joana Caetano, Filipa Barahona, Raquel Lopes, Emilie Arnault Carneiro, Bruno Costa‐Silva, Cristina M. Joao · 2020 · Journal of Molecular Medicine
37. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
    Johannes Moritz Waldschmidt, Andrew Jenho Yee, Tushara Vijaykumar, Ricardo A. Pinto, Julia Frede, Praveen Anand, Giada Bianchi, Guangwu Guo, Sayalee V. Potdar, Charles Seifer et al. · 2022 · Leukemia
38. Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution
    Rachel Rosenthal, Nicholas McGranahan, Javier Herrero, Charles Swanton · 2016 · Annual Review of Cancer Biology
39. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe
    Michèle Cavo, Evangelos Terpos, Joan Bargay, Hermann Einsele, Jim Cavet, Richard Greil, Edwin de Wit · 2018 · Expert Review of Hematology
40. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
    Charlotte Gran, Katarina Uttervall, Johanna Borg Bruchfeld, Ann Wallblom, Evren Alici, Gösta Gahrton, Hareth Nahi · 2019 · European Journal Of Haematology
41. Genomic Aberrations in Multiple Myeloma
    Salomon Manier, Karma Ziad Salem, Siobhan V. Glavey, Aldo Maria Roccaro, Irene M. Ghobrial · 2016 · Cancer treatment and research
42. Multiple Myeloma: Current Advances and Future Directions
    Thomas G. Martin, Carol Ann Huff · 2019 · Clinical Lymphoma Myeloma & Leukemia
43. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells
    Hiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, Shigeki Hirabayashi, Yasuhiro Murakawa, Masayuki Kobayashi, Anamaria Daniela Sarca, Yasuhiro Kazuma, Hiroyuki Matsui, Wataru Maruyama et al. · 2019 · Scientific Reports
44. A decade with whole exome sequencing in haematology
    Marcus Høy Hansen, Torsten Haferlach, Charlotte Guldborg Nyvold · 2019 · British Journal of Haematology
45. Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma
    Aline Rangel Pozzo, Pak Lok Ivan Yu, Sadhana Lal, Yasmin Asbaghi, Luiza Sisdelli, Pille Tammur, Anu Tamm, Mari Punab, Ludger Klewes, Sherif F. Louis et al. · 2021 · Cancers
46. Liquid biopsy in hematological malignancies: current and future applications
    Donatella Talotta, Mohammad Almasri, Chiara Cosentino, Gianluca Gaïdano, Riccardo Moia · 2023 · Frontiers in Oncology
47. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a
    Tengteng Yu, Chenxing Du, Xiaoke Ma, Weiwei Sui, Zhen Yu, Lanting Liu, Lei Qiang Zhao, Zhongqing Li, Jie Xu, Xiaojing Wei et al. · 2020 · Molecular Cancer Research
48. Utilizing next-generation sequencing in the management of multiple myeloma
    Marta Lionetti, Antonino Neri · 2017 · Expert Review of Molecular Diagnostics
49. Reconstructing the evolutionary history of multiple myeloma
    Francesco Maura, Even Holth Rustad, Eileen Mary Boyle, Gareth John Morgan · 2020 · Best Practice & Research Clinical Haematology
50. Genome‐defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B‐cell lymphoma
    Michelle J. Lee, Jean Louise Koff, Jeffrey M. Switchenko, Camber Ileen Jhaney, Robert Andrew Harkins, Sharvil Piyush Patel, Sandeep S. Davé, Christopher R. Flowers · 2020 · Cancer
51. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition
    Rui Liu, Jiyu Miao, Yachun Jia, Guangyao Kong, Fei Hong, Fangmei Li, Meng Zhai, Ru Zhang, Jiaxi Liu, Xuezhu Xu et al. · 2023 · Oncogene
52. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
    Carolina Terragna, Daniel Remondini, Marina Martello, Elena Zamagni, Lucia Pantani, Francesca F. Patriarca, Annalisa Pezzi, Giuseppe Levi, Massimo Offidani, Ilaria Proserpio et al. · 2015 · Oncotarget
53. Signatures of positive selection reveal a universal role of chromatin modifiers as cancer driver genes
    Luis Zapata, Hana Sušak, Oliver Drechsel, Marc R. Friedländer, Xavier Estivill, Stephan Ossowski · 2017 · Scientific Reports
54. Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing
    Meagan A. Jacoby, Eric James Duncavage, Matthew J. Walter · 2015 · Trends in cancer
55. Computational Methods for Characterizing Cancer Mutational Heterogeneity
    Fabio Vandin · 2017 · Frontiers in Genetics
56. Neutral tumor evolution in myeloma is associated with poor prognosis
    David C. Johnson, Oleg Lenive, Jonathan S. Mitchell, Graham Hunter Jackson, Roger G. Owen, Mark Trehane Drayson, Gordon Cook, John R Jones, Charlotte Pawlyn, Faith E. Davies et al. · 2017 · Blood
57. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
    Cristina Jiménez, María Jara‐Acevedo, Luis Antonio Corchete, David Castillo, Gonzalo R. Ordóñez, María Eugenia Sarasquete, Noemí Puig, Joaquín Martínez‐López, Isabel Prieto-Conde, María García‐Álvarez et al. · 2016 · Journal of Molecular Diagnostics
58. How Subclonal Modeling Is Changing the Metastatic Paradigm
    Geoff Macintyre, Peter Van Loo, Niall M. Corcoran, David C. Wedge, Florian M. Markowetz, Christopher M. Hovens · 2016 · Clinical Cancer Research
59. Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders
    Sridurga Mithraprabhu, Maoshan Chen, Ioanna Savvidou, Antonia Reale, Andrew G Spencer · 2021 · Leukemia
60. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities
    Nicola Giesen, Nagarajan Paramasivam, Umut H. Toprak, Daniel Hüebschmann, Jing Xu, Sebastian Uhrig, Mehmet Samur, Stella Bähr, Martina Fröhlich, Sadaf Shabbir Mughal et al. · 2022 · Haematologica
61. Somatic mutational profiles and germline polygenic risk scores in human cancer
    Yuxi Liu, Alexander Gusev, Yujing Jan Heng, Ludmil B. Alexandrov, Peter L. Kraft · 2022 · Genome Medicine
62. Drug targets and resistance mechanisms in multiple myeloma
    Janine Naß, Thomas Efferth · 2018 · Cancer Drug Resistance
63. Barcode-free next-generation sequencing error validation for ultra-rare variant detection
    Huiran Yeom, Yonghee Lee, Taehoon Ryu, Jinsung Noh, Amos Chungwon Lee, Han‐Byoel Lee, Eunji Kang, Seo Woo Song, Sunghoon Kwon · 2019 · Nature Communications
64. Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
    Kazuhito Suzuki, Kaichi Nishiwaki, Shingo Yano · 2021 · Cancers
65. Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma
    Amélie Giguère, Isabelle Raymond‐Bouchard, Vanessa Collin, Jean‐Sébastien Claveau, Josée Hébert, Richard LeBlanc · 2023 · Cancers
66. The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers
    Domenica Ronchetti, Valentina Traini, Ilaria Silvestris, G. Fabbiano, Francesco Passamonti, Niccolò Bolli, Elisa Taìana · 2024 · Cancer Gene Therapy
67. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
    Shaji Kunnathu Kumar · 2017 · Hematology
68. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
    Tiantian Ma, Jing Shi, Huasheng Liu · 2019 · Annals of Hematology
69. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation
    Tadahiko Matsumoto, Kotaro Shirakawa, Masaru Yokoyama, Hirofumi Fukuda, Anamaria Daniela Sarca, Sukenao Koyabu, Hiroyuki Yamazaki, Yasuhiro Kazuma, Hiroyuki Matsui, Wataru Maruyama et al. · 2019 · Scientific Reports
70. Quantifying the influence of mutation detection on tumour subclonal reconstruction
    Lydia Liu, Vinayak Bhandari, Adriana Salcedo, Shadrielle M. G. Espiritu, Quaid Morris, Thomas Kislinger, Paul Christopher Boutros · 2020 · Nature Communications
71. Constraints in cancer evolution
    Subramanian Venkatesan, Nicolai J. Birkbak, Charles Swanton · 2017 · Biochemical Society Transactions
72. Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
    Mohammad Alzrigat, Helena Jernberg‐Wiklund, Jonathan D. Licht · 2018 · Epigenomes
73. Multiple Myeloma Unpacked
    Francesca Gay, Edoardo Marchetti, Giuseppe Bertuglia · 2025 · Hematological Oncology
74. Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma
    Francesco Maura, Ola Landgren, Gareth John Morgan · 2020 · Clinical Cancer Research
75. Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism
    Ilaria Gritti, Veronica Basso, Darawan Rinchai, Federica Corigliano, Silvia Pivetti, Marco Gaviraghi, Dalia Rosano, Davide Mazza, Sara Barozzi, Marco Roncador et al. · 2022 · The EMBO Journal
76. Clonal Evolution in Multiple Myeloma
    Bita Fakhri, Ravi Vij · 2016 · Clinical Lymphoma Myeloma & Leukemia
77. Multiple Myeloma Genomics: A Systematic Review
    Casey J. Weaver, Joseph D Tariman · 2017 · Seminars in Oncology Nursing
78. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies
    Irene Dogliotti, Daniela Drandi, Elisa Genuardi, Simone Ferrero · 2018 · Journal of Clinical Medicine
79. Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
    Hitomi Hosoya, Mia A. Carleton, Kailee L. Tanaka, Brian J. Sworder, Shriya Syal, Bita Sahaf, Alisha M. Birk, Oscar Silva, Henning Stehr, Vanna N. Hovanky et al. · 2025 · Nature Communications
80. Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
    Aleksander Salomon‐Perzyński, Krzysztof Jamroziak, Eliza Głodkowska‐Mrówka · 2021 · Diagnostics
81. Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma
    Juan‐José Garcés, Jesús F. San Miguel, Bruno Paiva · 2022 · Cancers
82. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
    Jonas Schwestermann, Andrej Bešše, Christoph Driessen, Lenka Bešše · 2022 · Frontiers in Oncology
83. Hexokinase-2 Expression in 11C-Methionine–Positive, 18F-FDG–Negative Multiple Myeloma
    Stefan Kircher, Antje Stolzenburg, Klaus Martin Kortüm, Malte Kircher, Matteo Da Vià, Samuel Samnick, Andreas Konrad Buck, Hermann Einsele, Andreas Rosenwald, Constantin Lapa · 2018 · Journal of Nuclear Medicine
84. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
    Adamia, Sophia, Bhatt, Shruti, Wen, Kenneth, Chyra, Zuzana, Fell, Geoffrey G., Tai, Yu-Tzu, Pioso, Marisa S., Abiatari, Ivane, Letai, Anthony, Dorfman, David M. et al. · 2022 · Leukemia
85. Effect of MAPK activation via mutations in <i>NRAS</i>, <i>KRAS</i> and <i>BRAF</i> on clinical outcome in newly diagnosed multiple myeloma
    Perroud, Camille, Thurian, Dario, Andres, Martin, Künzi, Arnaud, Wiedemann, Gertrud, Zeerleder, Sacha, Bacher, Ulrike, Pabst, Thomas, Banz, Yara, Porret, Naomi et al. · 2023 · Hematological Oncology
86. Cancer stem cells modulate patterns and processes of evolution in cancers
    Lucie Laplane · 2018 · Biology & Philosophy
87. ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
    Giada Bianchi, Peter G. Czarnecki, Matthew Ho, Aldo Maria Roccaro, Antonio Sacco, Yawara Kawano, Annamaria Gullà, Anıl Aktaş Samur, Tianzeng Chen, Kenneth Wen et al. · 2021 · Blood Cancer Discovery
88. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
    Yuting Yan, Xiaoqi Qin, Jiahui Liu, Huishou Fan, Wenqiang Yan, Lanting Liu, Chenxing Du, Zhen Yu, Yan Xu, Mu Hao et al. · 2021 · Blood Advances
89. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
    Parvathi Sudha, Aarif Ahsan, Cody Ashby, Tasneem Kausar, Akhil Khera, Mohammad H. Kazeroun, Chih-Chao Hsu, Lin Wang, Evelyn Fitzsimons, Outi Salminen et al. · 2022 · Clinical Cancer Research
90. In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
    Anıl Aktaş Samur, Mariateresa Fulciniti, Hervé Avet‐Loiseau, Michael A. Lopez, Sanika Derebail, Jill Corre, Stéphane Minvielle, Florence Magrangeas, Philippe Moreau, Kenneth Carl Anderson et al. · 2022 · Blood Cancer Journal
91. Recent advances in understanding multiple myeloma
    Binod Dhakal, Saulius Kazmiems Girnius, Parameswaran Hari · 2016 · F1000Research
92. Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect
    Chung‐Han Lee, Gunes Gundem, William Lee, Ying‐Bei Chen, Justin R. Cross, Yiyu Dong, Almedina Redzematovic, Roy Mano, Elizabeth Y. Wei, Emily H. Y. Cheng et al. · 2017 · JCO Precision Oncology
93. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
    Gang An, Yuting Yan, Yan Xu, Xuehan Mao, Jiahui Liu, Huishou Fan, Qi Wang, Chenxing Du, Zengjun Li, Shuhua Yi et al. · 2019 · Leukemia
94. A highly heterogeneous mutational pattern in POEMS syndrome
    Jia Chen, Xuemin Gao, Hao Zhao, Hao Cai, Lu Zhang, Xinxin Cao, Daobin Zhou, Jian Li · 2020 · Leukemia
95. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
    Matteo Da Vià, Bachisio Ziccheddu, Akihiro Maeda, Filippo Bagnoli, Giulia Perrone, Niccolò Bolli · 2020 · HemaSphere
96. SP140L, an Evolutionarily Recent Member of the SP100 Family, Is an Autoantigen in Primary Biliary Cirrhosis
    Mario Saare, Uku Hämarik, Rainis Venta, Marina Panarina, Chiara Zucchelli, Maire Pihlap, Anu Remm, Kai E. Kisand, Urve Toots, Kaidi Möll et al. · 2015 · Journal of Immunology Research
97. Germline Risk Contribution to Genomic Instability in Multiple Myeloma
    Siegfried Janz, Fenghuang Zhan, Fumou Sun, Yan Cheng, Michael D. Pisano, Ye Yang, Hartmut Goldschmidt, Parameswaran Hari · 2019 · Frontiers in Genetics
98. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy
    Maria Aslani Gkotzamanidou, Elisavet Terpou, Nikolaos K. Kentepozidis, Evangelos Terpos · 2021 · International Journal of Molecular Sciences
99. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
    Yu-Hsiu Tony Lin, Gregory P. Way, Benjamin G. Barwick, Margarette C. Mariano, Makeba Marcoulis, Ian Ferguson, Christoph Driessen, Lawrence Boise, Casey S. Greene, Arun P. Wiita · 2019 · Blood Advances
100. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma
     Marcella Kaddoura, David Dingli, Francis K. Buadi, Martha Q. Lacy, Morie Abraham Gertz, Angela A. Dispenzieri, Prashant Kapoor, Yi L. Hwa, Amie L Fonder, Miriam Hobbs et al. · 2021 · Blood Advances